- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Raid: Telangana DCA seizes overpriced anti-cancer medicine in Karimnagar
![Raid: Telangana DCA seizes overpriced anti-cancer medicine in Karimnagar Raid: Telangana DCA seizes overpriced anti-cancer medicine in Karimnagar](https://medicaldialogues.in/h-upload/2024/01/27/750x450_231031-raid-50.webp)
Drugs Control Administration officials, Telangana has seized overpriced anti-cancer medicine 'Dacazee 500 Injection' (Dacarbazine Injection IP 500 mg), during the raids at a medical shop located in Karimnagar. The raids were carried out on 11th and 12th July, 2024. The MRP indicated was very high compared to the Ceiling Price fixed for the product by the Central Government.
Dacazee 500 Injection (Dacarbazine Injection IP 500 mg) is used to treat cancer of the lymph system (Hodgkin’s disease) and malignant melanoma (a type of skin cancer).
The product Dacarbazine Injection 500 mg sold under brand name ‘Dacazee 500 Injection’ is under price control as per Drugs (Prices Control) Order, 2013 and the price of product shall be in accordance with the ‘Ceiling Price’ fixed by National Pharmaceutical Pricing Authority (NPPA), Government of India.
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751